Delphinidins for Health & Longevity

Evidence Review created on 10/19/2026 using AI4L + evidence-mcp / Gemini 4 Argon

Also known as: Delphinidin, Delphinidin Chloride, Delphinidin-3-glucoside, Delphinidin-3-O-glucoside, Delphinidin-3,5-diglucoside, Delphinidin-3-sambubioside, Delphinidin-3-sambubioside-5-glucoside, Delphinidin-3-rutinoside, Myrtillin, Delphinol, MaquiBright

Motivation

Delphinidins are deep blue-red plant pigments found in high concentrations in Patagonian maqui berries, bilberries, blackcurrants, and hibiscus flowers. Among natural plant pigments, they carry three oxygen-hydrogen groups on their side ring, a structural feature that drives scientific interest in how they interact with cellular enzymes, blood vessel linings, and intestinal sugar transporters. For proactive adults focused on health and longevity, delphinidins attract attention as an oral compound studied for post-meal blood sugar control, blood vessel flexibility, and tear gland function.

Indigenous communities in southern Chile traditionally consumed wild maqui berries for stamina, and modern extraction methods now concentrate sugar-bound delphinidin pigments into standardized oral capsules. Clinical researchers have investigated whether these concentrated berry extracts or isolated pigments alter blood sugar handling, cholesterol profiles, or eye dryness, while absorption studies have examined why so little intact pigment reaches the bloodstream after oral intake.

This review examines the human clinical trials, absorption and breakdown studies, and cell and animal experiments on delphinidins and delphinidin-rich extracts. It evaluates the strength of evidence across blood sugar, blood vessel, and eye outcomes, notes where commercial sponsorship or mixed berry formulations limit certainty, and outlines practical dosing, safety, and monitoring considerations.

Benefits - Risks - Protocol - Conclusion

This section curates accessible expert overviews and narrative reviews covering delphinidins, delphinidin-rich maqui berry extracts, and the parent berry anthocyanin class.

Neither general web searches nor direct on-site searches of Andrew Huberman (hubermanlab.com) and Chris Kresser (chriskresser.com) returned coverage of delphinidins or maqui berry extracts, while Peter Attia (peterattiamd.com) and Lifespan.io (lifespan.io) lack standalone delphinidin pages and are represented above by articles on their parent flavonoid and berry anthocyanin class.

Grokipedia

Delphinidin

Summarizes the chemical structure, pH-dependent color shifts, biosynthesis, dietary sources, and molecular pharmacology of delphinidin and its natural glycosides, including myrtillin and delphinidin-3-sambubioside.

Examine

No dedicated Examine article exists for delphinidins or standardized maqui berry extract as of October 2026.

ConsumerLab

No dedicated ConsumerLab article or product review exists for delphinidins as of October 2026.

Systematic Reviews

This section summarizes systematic reviews and meta-analyses evaluating delphinidin-rich extracts and structure-specific anthocyanin supplementation across cardiometabolic, glycemic, ocular, and hemostatic outcomes.

While these systematic reviews evaluate the claimed cardiometabolic, ocular, and antiplatelet benefits, no systematic review or meta-analysis specifically dedicated to the principal risks, adverse effects, or financial costs of delphinidins exists in the literature.

Mechanism of Action

Delphinidin (3,3’,4’,5,5’,7-hexahydroxyflavylium) is a positively charged anthocyanidin whose trihydroxylated B-ring provides high electron-donating capacity. In plants and supplements, it occurs mainly as 3-O-glycosides: delphinidin-3-sambubioside-5-glucoside, delphinidin-3-sambubioside, and delphinidin-3-O-glucoside (myrtillin).

In the small intestine, delphinidin glycosides competitively inhibit sodium-glucose cotransporter-1 (SGLT1, an intestinal glucose transporter) on enterocyte brush-border membranes, slowing glucose absorption (Hidalgo et al., 2014), and stimulate L-cells to secrete GLP-1. In vascular and neural tissues, delphinidin activates endothelial nitric oxide synthase (eNOS, the enzyme producing vessel-relaxing nitric oxide), activates nuclear factor erythroid 2-related factor 2 (Nrf2, an antioxidant transcription factor), inhibits nuclear factor kappa B (NF-κB, an inflammatory transcription factor), and activates the adenosine monophosphate-activated protein kinase (AMPK, a cellular energy sensor) and sirtuin 1 (SIRT1, a stress-resistance deacetylase) pathway (Liu et al., 2025). In platelets, delphinidin-3-glucoside inhibits phosphoinositide 3-kinase/protein kinase B (PI3K/Akt, a survival and platelet-activation pathway) signaling (Song et al., 2014).

Competing explanations exist regarding systemic activity because intact delphinidins have <1% oral bioavailability: after 1,000 mg Delphinol in humans, delphinidin-3-O-glucoside reaches a peak plasma concentration (Cmax, highest blood level) of 34.7 nmol/L at a time to peak concentration (Tmax, time to peak level) of 1.0 hour (Schön et al., 2018, co-authored by Anklam Extrakt GmbH), with an elimination half-life (t1/2, time for levels to halve) of 3.34 hours for delphinidin-3-sambubioside (Frank et al., 2005). Colonic cleavage into gallic acid, followed by conjugation via catechol-O-methyltransferase (COMT, a catechol-methylating enzyme), uridine 5’-diphospho-glucuronosyltransferases (UGTs, glucuronide-conjugating enzymes), and sulfotransferases (SULTs, sulfate-conjugating enzymes), indicates phenolic metabolites drive systemic effects.

Historical Context & Evolution

Delphinidin was first isolated and named in the early twentieth century by Richard Willstätter from the deep violet petals of Delphinium consolida (larkspur). Shortly thereafter, the 3-glucoside of delphinidin—termed myrtillin—was extracted from bilberry (Vaccinium myrtillus) leaves and fruit. In 1927, Frederick Allen investigated oral myrtillin in diabetic animals and human patients, observing reduced glycosuria and proposing it as an oral agent to reduce insulin requirements. Interest in crude leaf extracts waned in the mid-twentieth century as purified injectable insulins and synthetic oral hypoglycemics offered greater potency and batch-to-batch standardization, though those early myrtillin findings were later revisited when modern chromatography identified specific anthocyanin structures.

Simultaneously, indigenous Mapuche communities in southern Chile had long harvested wild Patagonian maqui berries (Aristotelia chilensis) as a concentrated nutritional source for physical endurance and mucosal inflammation. Analytical chemistry in the early 2000s revealed that Aristotelia chilensis possesses an unusually high concentration of delphinidin glycosides—accounting for roughly 75–85% of its total anthocyanins, including unique di- and tri-glycosides such as delphinidin-3-sambubioside-5-glucoside.

This structural discovery shifted scientific focus from generic dietary antioxidant capacity—a concept increasingly questioned after high-dose synthetic vitamin trials failed to improve longevity outcomes—toward structure-specific polyphenol signaling. Over the past decade, standardized maqui extracts (Delphinol and MaquiBright, ≥25% delphinidins) entered human RCTs targeting SGLT1-mediated postprandial glycemia, lacrimal gland oxidative stress, and eNOS-dependent endothelial function, while ongoing debate centers on whether purified delphinidins outperform whole berry extracts.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High because no human clinical trials across multiple independent research groups have tested isolated, purified delphinidins on validated clinical endpoints; all human trials have administered multi-component berry extracts or mixed anthocyanin preparations.

Medium 🟩 🟩

No benefit reaches Medium because human RCTs demonstrating improvements in glycemic, vascular, lipid, or ocular endpoints tested standardized maqui berry extracts (≥25% delphinidins alongside cyanidin glycosides and other polyphenols) or mixed berry anthocyanins, which constitute indirect evidence for delphinidins and cap at Low.

Low 🟩

Tear Production and Dry Eye Symptom Relief ⭕️ Not Central to Health & Longevity

RCTs (Yamashita et al., 2019, sponsored by Oryza Oil & Fat Chemical Co.; Kundu et al., 2023) and pilot data (Hitoe et al., 2014, Oryza Oil & Fat Chemical Co.) show 30–60 mg/day maqui extracts (MaquiBright or Maqvue) increase tear fluid. Evidence is indirect (extracts) and bears on ocular comfort.

Magnitude: Bilateral Schirmer’s test tear secretion increased by +6.4 ± 8.1 mm/5 min (mean ± standard deviation [SD, spread around the average], from 7.2 ± 1.2 mm to 13.6 ± 8.4 mm) with 60 mg/day MaquiBright over 4 weeks, which was significantly greater than the placebo group change by analysis of covariance (p = 0.005; exact placebo delta and 95% confidence interval [CI, range expected to contain the true effect] not reported in main text) (Yamashita et al., 2019).

Acute Postprandial Glucose and Insulin Attenuation

Crossover trials (Hidalgo et al., 2014; Alvarado et al., 2016, co-authored by Delphinol trademark holders MNL-Chile and Horphag Research) show single 60–200 mg Delphinol doses blunt post-meal glucose and insulin peaks via SGLT1 inhibition. Evidence is indirect because studies tested maqui extract rather than isolated delphinidins.

Magnitude: A single 180 mg Delphinol dose reduced fasting glucose by 3.61 mg/dL and fasting insulin by 3.4 µIU/mL relative to untreated basal control (p < 0.05), while 120 mg significantly lowered 30-minute post-load glucose (p < 0.05) and 60–180 mg dose-dependently lowered maximum glucose peak height (linear regression slope p = 0.0273; 95% CI not reported) versus untreated control (Alvarado et al., 2016).

Vascular Endothelial Function and Arterial Stiffness

A meta-analysis of RCTs (Avendano et al., 2026, partially supported by the United States Highbush Blueberry Council) found delphinidin-predominant supplementation improved flow-mediated dilation (FMD, ultrasound blood-vessel widening) and pulse wave velocity (PWV, arterial stiffness speed) via eNOS activation. Evidence is indirect because trials tested delphinidin-rich berry extracts.

Magnitude: Delphinidin-predominant interventions increased acute FMD by 1.69% more than placebo (95% CI: 1.20% to 2.18%) and chronic FMD by 1.59% more than placebo (95% CI: 1.21% to 2.04%), and reduced chronic PWV by -0.33 m/s versus placebo (95% CI: -0.62 to -0.05 m/s) (Avendano et al., 2026).

Dyslipidemia and Long-Term Glycemic Modulation ⚠️ Conflicted

A meta-analysis (Araki et al., 2021) and open-label trial (Alvarado et al., 2016, co-authored by Horphag Research) reported lipid and glycated hemoglobin (HbA1c, three-month blood sugar) gains, whereas RCTs (Aboufarrag et al., 2022; Davinelli et al., 2015) found no effect. Evidence is indirect (extracts) and conflicted, leaving efficacy unproven.

Magnitude: Delphinidin-predominant supplementation changed low-density lipoprotein cholesterol (LDL-C, atherogenic blood cholesterol) by -0.28 mmol/L (95% CI: -0.42 to -0.13), triglycerides by -0.24 mmol/L (95% CI: -0.41 to -0.07), and high-density lipoprotein cholesterol (HDL-C, protective blood cholesterol) by +0.11 mmol/L (95% CI: 0.04 to 0.19) versus placebo (Araki et al., 2021), whereas 320 mg/day bilberry anthocyanins showed no LDL-C change versus placebo (Aboufarrag et al., 2022).

Platelet Hyperreactivity Attenuation

A 24-week RCT in 150 hypercholesterolemic adults (Song et al., 2014) and a systematic review (Tamer et al., 2022) showed reduced platelet granule secretion via PI3K/Akt inhibition. Evidence is indirect because participants took a purified bilberry-blackcurrant anthocyanin blend containing delphinidin-3-glucoside and cyanidin glycosides rather than isolated delphinidins.

Magnitude: Supplementation with 320 mg/day purified anthocyanins significantly reduced plasma β-thromboglobulin, soluble P-selectin, and regulated on activation, normal T cell expressed and secreted (RANTES, a platelet-derived inflammatory chemokine) compared with placebo (p < 0.05) in hypercholesterolemic adults; no numerical between-group difference figures are reported in the available source (Song et al., 2014).

Autonomic Heart Rate Variability and Psychophysical Resilience

A 30-day single-blind RCT in 30 healthy adults (Cavezzi et al., 2023) reported improved heart rate variability (HRV, beat-to-beat heart interval variation) and 12-Item Short Form Survey (SF-12, a health questionnaire) mental scores with 1,000 mg/day maqui nutraceutical. Evidence is indirect because whole maqui powder was tested.

Magnitude: Autonomic nervous system coordination on HRV testing increased within the 1,000 mg/day maqui group (p = 0.05) while decreasing in the untreated control group, and SF-12 mental component scores improved within the maqui group (p = 0.02) over 30 days in healthy adults; outcomes were not compared between groups and the literature reports no numerical outcome figures (Cavezzi et al., 2023).

Speculative 🟨

Systemic Lipid Peroxidation Reduction

In a 4-week RCT (Davinelli et al., 2015), 450 mg/day Delphinol lowered plasma oxidized low-density lipoprotein (oxLDL, free-radical-damaged cholesterol) and urinary 8-iso-prostaglandin F2α. Both markers are unvalidated oxidative biomarkers rather than clinical endpoints.

Cellular Senescence and Neuroinflammation Mitigation

In Alzheimer’s mice (Liu et al., 2025), delphinidin reduced microglial senescence, p16/p21 (cell-cycle arrest senescence proteins), and amyloid-β plaques via AMPK/SIRT1 activation. No controlled human trials exist, so evidence is preclinical only.

Bone Density Preservation

In osteopenic mice (Nagaoka et al., 2019, co-authored by Anklam Extrakt GmbH), delphinidin-enriched maqui extract inhibited NF-κB-mediated osteoclastogenesis and promoted bone formation. No controlled human trials exist, so evidence is preclinical only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in phase II metabolizing enzymes—specifically COMT rs4680 Val158Met (a variant slowing catechol methylation), UGTs, and SULTs—alter the methylation, glucuronidation, and clearance of delphinidin and its active phenolic metabolites (gallic acid and 3-O-methylgallic acid), modifying systemic vascular exposure (Schön et al., 2018).
  • Baseline biomarker levels: Glycemic and lipid reductions occur primarily in individuals with elevated baseline fasting glucose (100–125 mg/dL), insulin resistance, or dyslipidemia (Alvarado et al., 2016; Araki et al., 2021), whereas metabolically healthy adults show minimal lipid changes (Aboufarrag et al., 2022).
  • Pre-existing health conditions: Prediabetes, hypercholesterolemia, smoking-induced oxidative stress, and moderate dry eye disease amplify measurable responses in postprandial glucose, platelet reactivity, and tear fluid secretion (Hidalgo et al., 2014; Song et al., 2014; Yamashita et al., 2019).
  • Gut microbiome composition: Because >95% of ingested delphinidin glycosides reach the colon where bacterial β-glucosidases cleave them into bioavailable gallic acid and phloroglucinol aldehyde, inter-individual differences in colonic microbiota strongly govern systemic vascular and anti-inflammatory benefits (Avendano et al., 2026).
  • Sex-based differences: Human pharmacokinetic and clinical efficacy trials of standardized maqui extracts (Schön et al., 2018; Yamashita et al., 2019) enrolled both men and women and detected no statistically significant sex differences in plasma delphinidin absorption or tear-production response.
  • Age-related considerations: Older adults (aged 50–75 years) with age-related endothelial stiffness, declining lacrimal output, or impaired glucose tolerance exhibit larger absolute improvements in FMD, PWV, and postprandial glucose than young adults with optimal baseline vascular elasticity (Alvarado et al., 2016; Avendano et al., 2026).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High because human clinical trials across multiple research groups tested standardized berry extracts rather than isolated delphinidins and reported no statistically significant increase in treatment-emergent adverse events compared with placebo.

Medium 🟥 🟥

No risk reaches Medium because single-trial and single-group human studies of delphinidin-rich extracts up to 1,000 mg/day found no treatment-related clinical adverse events or hepatic, renal, or hematological toxicities relative to control groups.

Low 🟥

Speculative 🟨

Mild Gastrointestinal Discomfort

Concentrated berry extracts could theoretically cause mild nausea or bowel changes via astringency, though botanical reviews and human trials report zero adverse events (Benatrehina et al., 2018; Yamashita et al., 2019). Evidence is mechanistic only.

Additive Hypoglycemia with Antidiabetic Therapy

Delphinidin-rich extracts inhibit SGLT1 and lower postprandial glucose (Hidalgo et al., 2014; Alvarado et al., 2016). Pairing them with insulin or secretagogues could theoretically cause hypoglycemia, though no clinical cases exist, making evidence mechanistic only.

Platelet Aggregation Inhibition and Bleeding Potentiation

Delphinidin-3-glucoside inhibits platelet granule secretion via PI3K/Akt signaling (Song et al., 2014; Tamer et al., 2022). Concurrent anticoagulant use poses a theoretical bleeding risk, though no clinical bleeding events are reported, making evidence mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: Slow-activity variants in COMT, UGTs, or SULTs theoretically prolong systemic exposure to conjugated delphinidin metabolites (Schön et al., 2018), though no human studies link these variants to increased adverse events.
  • Baseline biomarker levels: Individuals with low-normal baseline fasting glucose (<80 mg/dL) or low normal platelet reactivity face higher theoretical susceptibility to glucose drops or easy bruising when taking high-dose delphinidin extracts (Alvarado et al., 2016; Song et al., 2014).
  • Pre-existing health conditions: Peptic ulcer disease, bleeding disorders, or unstable glycemic control on insulin therapy may heighten theoretical sensitivity to polyphenol astringency, antiplatelet signaling, or SGLT1-mediated glucose lowering (Tamer et al., 2022; Hidalgo et al., 2014).
  • Sex-based differences: Clinical trials of Delphinol and MaquiBright across male and female cohorts reported no sex-specific differences in adverse event rates, tolerability, or clinical chemistry parameters (Yamashita et al., 2019; Schön et al., 2018).
  • Age-related considerations: Older adults on polypharmacy—particularly concurrent anticoagulants, antiplatelets, or oral hypoglycemics—carry a higher theoretical risk of pharmacodynamic interactions despite unchanged intrinsic tolerability of delphinidin extracts up to age 85 (NCT04914312).

Key Interactions & Contraindications

  • Antidiabetic drugs (metformin, glimepiride, insulin glargine, empagliflozin): Monitor (theoretical). Delphinidins inhibit intestinal SGLT1 and lower postprandial glucose (Hidalgo et al., 2014), potentially causing additive hypoglycemia; clinical management involves blood glucose monitoring and medication dose adjustment if needed.
  • Prescription anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel): Caution (theoretical). Delphinidin-3-glucoside inhibits PI3K/Akt-dependent platelet granule secretion (Song et al., 2014), which may potentiate bleeding risk; clinical protocols monitor for bruising and pause supplementation 7–14 days before elective surgery.
  • Over-the-counter nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen): Caution (theoretical). Concurrent use combines cyclooxygenase-mediated antiplatelet effects with delphinidin-mediated inhibition of platelet activation (Tamer et al., 2022), theoretically increasing mucosal or gastrointestinal bleeding risk when used chronically.
  • Cytochrome P450 3A4 (CYP3A4, a drug-metabolizing liver enzyme) substrates (atorvastatin, midazolam, cyclosporine): Monitor (theoretical). Delphinidin weakly inhibits CYP3A4 in vitro, but nanomolar human plasma levels (Cmax ≈ 35 nmol/L, Schön et al., 2018) make clinical enzyme inhibition unlikely.
  • Glucose-lowering and antiplatelet supplements (berberine, alpha-lipoic acid, Ginkgo biloba, marine omega-3 fatty acids): Monitor (theoretical). Co-administration may cause additive postprandial glucose drops or additive platelet inhibition; mitigation involves staggered dosing schedules and monitoring of fasting glucose and bruising.
  • Non-heme iron supplements (ferrous sulfate, ferrous bisglycinate): Caution (theoretical). Trihydroxylated B-ring polyphenols chelate non-heme iron in the intestinal lumen, reducing oral iron absorption; separating delphinidin extracts and oral iron supplements by at least 2 hours mitigates chelation.

Populations who should avoid Delphinidins:

  • Individuals with diabetes mellitus or taking hypoglycemic medications: Excluded from glycemic and vascular clinical trials (NCT07263802; NCT07196059) due to potential SGLT1-mediated blood glucose reductions and unstudied pharmacodynamic interactions with prescribed antidiabetic therapies.
  • Patients with stage 5 chronic kidney disease (CKD, progressive loss of kidney function) with estimated glomerular filtration rate (eGFR, a blood measure of kidney filtration) <15 mL/min/1.73 m², or acute kidney injury within 3 months: Excluded from renal trials (NCT07776925).
  • Pregnant or lactating women: Excluded across human clinical trials (NCT07776925; NCT07263802; Kundu et al., 2023) due to the absence of reproductive toxicology and fetal safety data for concentrated delphinidin extracts.
  • Patients with prior corneal surgery, severe dry eye with Schirmer’s test <5 mm/5 min, or taking oral anticoagulants (warfarin): Excluded from ocular and systemic trials (Kundu et al., 2023; NCT04914312; NCT07776925) due to ocular confounding or PI3K/Akt-mediated antiplatelet signaling (Song et al., 2014).

Risk Mitigation Strategies

Doses, timings, and monitoring intervals below follow common practice unless cited.

  • Pre-meal administration with carbohydrates: Administering 60–180 mg Delphinol 60 minutes before glucose (Alvarado et al., 2016) or 200 mg 30 minutes before carbohydrate meals (Hidalgo et al., 2014) mitigates gastric tannin irritation and theoretical fasting hypoglycemia.
  • Gradual dose titration: Starting at the lowest clinically studied acute dose of 60 mg/day standardized maqui extract (Alvarado et al., 2016) for 1–2 weeks before escalating to 180 mg/day (Alvarado et al., 2016) mitigates transient gastrointestinal discomfort or bowel changes.
  • Temporal separation from oral iron: Separating delphinidin administration from non-heme iron supplements or iron-fortified meals by at least 2 hours prevents intraluminal polyphenol-iron chelation and mitigates potential reductions in ferritin levels.
  • Perioperative discontinuation: Pausing delphinidin and concentrated anthocyanin supplementation 7–14 days prior to surgical or dental procedures mitigates potential prolongation of bleeding time from PI3K/Akt-mediated antiplatelet signaling (Song et al., 2014).
  • Capillary glucose monitoring with concurrent secretagogues: Checking fasting and 1-hour postprandial glucose during the first 2 weeks of co-administration with antidiabetic agents—and pausing supplementation if glucose falls below 70 mg/dL—mitigates additive hypoglycemia.

Therapeutic Protocol

Other parameters without a citation (such as titration steps, split-dosing schedules, and cycling) reflect common practice.

  • Standardized extract dosing: Trials use 60 mg/day MaquiBright for dry eyes (Yamashita et al., 2019), 180 mg/day Delphinol for glycemia and lipids (Alvarado et al., 2016), and 450 mg/day Delphinol for oxidative stress (Davinelli et al., 2015).
  • Purified anthocyanin alternative: Cardiovascular and antiplatelet RCTs use 320 mg/day of purified bilberry and blackcurrant anthocyanins (standardized to delphinidin-3-glucoside and cyanidin-3-glucoside, popularized in academic lipid research using Medox capsules) (Song et al., 2014; Aboufarrag et al., 2022).
  • Pharmacokinetic half-life: Intact delphinidin-3-O-glucoside reaches Tmax at 1.0 ± 0.3 hours and clears toward baseline within 8 hours (Schön et al., 2018), with an elimination t1/2 of 3.34 hours for delphinidin-3-sambubioside (Frank et al., 2005).
  • Best time of day: Delphinol is administered orally at 200 mg 30 minutes before rice meals (Hidalgo et al., 2014), 60–180 mg 60 minutes before glucose (Alvarado et al., 2016), or 180 mg before breakfast (Alvarado et al., 2016).
  • Single versus split dosing: Given the 3.3-hour t1/2, 180–450 mg/day regimens are administered once before breakfast (Alvarado et al., 2016) or split into 150 mg three times daily with meals (Davinelli et al., 2015).
  • Genetic polymorphisms: Individuals with rapid-metabolizing COMT Val/Val genotypes or high UGTs activity clear methylated and glucuronidated delphinidin metabolites faster and may favor split twice- or thrice-daily dosing over single daily boluses.
  • Sex-based differences: Human pharmacokinetic and clinical trials demonstrate comparable Cmax, Tmax, and clinical efficacy in men and women, requiring no sex-based dose adjustments (Schön et al., 2018; Yamashita et al., 2019).
  • Age-related considerations: Adults aged 50–85 years tolerate 180–600 mg/day standardized maqui extract without dose reduction (Alvarado et al., 2016; NCT04914312), though older adults on polypharmacy typically begin at 60 mg/day.
  • Baseline biomarkers and pre-existing conditions: Normoglycemic adults (<100 mg/dL) typically use 60 mg/day for ocular or endothelial support (Yamashita et al., 2019), whereas adults with prediabetes (100–125 mg/dL) or dyslipidemia use 180–320 mg/day (Alvarado et al., 2016).

Discontinuation & Cycling

  • Short-term versus continuous duration: Clinical trials test continuous daily intake for 4 to 24 weeks (Yamashita et al., 2019; Song et al., 2014); because delphinidins do not accumulate in tissues, sustained metabolic and vascular effects require ongoing administration.
  • Biomarker washout after stopping: In the Davinelli et al. (2015) trial, reductions in plasma oxLDL and urinary F2-isoprostanes achieved during 4 weeks of Delphinol supplementation returned to baseline levels within 40 days after discontinuation.
  • Withdrawal effects and tapering: Abrupt discontinuation produces no physiological withdrawal syndrome, rebound hyperglycemia, or rebound ocular dryness in human trials, so no tapering-off protocol is required.
  • Cycling considerations: Receptor desensitization or tolerance to SGLT1 inhibition and eNOS activation has not been observed over 12–24 weeks (Alvarado et al., 2016; Song et al., 2014), so cycling is unnecessary for maintaining efficacy.

Sourcing and Quality

  • Standardized extracts versus whole berry powders: Freeze-dried maqui berry powder contains variable anthocyanin levels (2–5% by weight), whereas standardized extracts (Delphinol and MaquiBright) use resin chromatography to guarantee ≥35% total anthocyanins and ≥25% total delphinidins (Watson & Schönlau, 2015).
  • Analytical verification by chromatography: Authentic delphinidin supplements verify individual glycoside identity and potency using high-performance liquid chromatography rather than nonspecific colorimetric spectrophotometry, which cannot distinguish delphinidin glycosides from synthetic food dyes or inexpensive peanut-skin and grape-skin polyphenols.
  • Stability and packaging protection: Delphinidin flavylium cations degrade rapidly when exposed to alkaline pH, heat, oxygen, or light; high-quality oral capsules use opaque blister packs or dark amber bottles with desiccants and organic acid stabilizers to preserve potency.
  • Reputable suppliers and third-party testing: Clinical trials rely on patented ingredients—Delphinol (MNL-Chile / Anklam Extrakt), MaquiBright (Oryza Oil & Fat Chemical Co.), and Medox—encapsulated under Good Manufacturing Practice standards with independent purity verification from United States Pharmacopeia or National Sanitation Foundation.

Practical Considerations

  • Time to effect: Postprandial glucose blunting and acute FMD increases occur within 60–120 minutes (Alvarado et al., 2016; Avendano et al., 2026), tear secretion improves by 4 weeks (Yamashita et al., 2019), and HbA1c and lipid shifts require 8–12 weeks (Alvarado et al., 2016).
  • Common pitfalls: Taking unstandardized freeze-dried maqui powder at capsule doses (e.g., 500 mg, yielding <15 mg delphinidins instead of the 45–150 mg used in Delphinol trials), or taking capsules hours after meals when targeting SGLT1-mediated postprandial glucose spikes.
  • Regulatory status: Delphinidins and standardized maqui extracts are regulated in the United States as dietary supplement ingredients under the Dietary Supplement Health and Education Act of 1994 and carry no United States Food and Drug Administration approval for treating diabetes, dyslipidemia, or dry eyes.
  • Cost and accessibility: Standardized Delphinol (60–180 mg) and MaquiBright (60 mg) oral capsules are widely accessible over the counter at moderate monthly cost ($15–$35/month), whereas isolated analytical-grade delphinidin chloride is prohibitively expensive and restricted to laboratory research.

Interaction with Foundational Habits

  • Sleep: Indirect potentiating interaction. In adults with high digital screen exposure, 60 mg/day MaquiBright reduced ocular fatigue, shoulder stiffness, and eye dryness (Yamashita et al., 2019), while 1,000 mg/day maqui berry improved autonomic parasympathetic recovery (Cavezzi et al., 2023); morning or pre-dinner dosing avoids nocturnal gastrointestinal activity.
  • Nutrition: Direct potentiating and blunting interactions. Administering Delphinol 15–30 minutes before high-glycemic carbohydrate meals directly blunts postprandial glucose and insulin via SGLT1 inhibition (Hidalgo et al., 2014), whereas co-ingestion with alkaline baking soda degrades the flavylium cation and co-ingestion with iron-rich meals blunts non-heme iron absorption.
  • Exercise: Indirect interaction (vascular perfusion support versus potential blunting of acute oxidative training signals). While eNOS-mediated FMD increases (Avendano et al., 2026) aid muscle perfusion, high-dose exogenous antioxidants near workouts may blunt reactive-oxygen-species-mediated mitochondrial adaptations; protocols typically space high doses (≥450 mg) 3–4 hours from training.
  • Stress management: Direct potentiating interaction. A 30-day RCT of 1,000 mg/day maqui berry nutraceutical demonstrated improved autonomic nervous system coordination on HRV monitoring and higher SF-12 mental resilience scores (Cavezzi et al., 2023), complementing vagal breathing and neuroendocrine stress-recovery practices.

Monitoring Protocol & Defining Success

Before initiating delphinidin supplementation, baseline laboratory and clinical testing establishes pre-intervention glycemic, insulinemic, lipid, vascular, and ocular benchmarks while screening for low-normal fasting glucose (<80 mg/dL) or stage 5 renal impairment (eGFR <15 mL/min/1.73 m²). Baseline blood draws are collected in the morning after an 8–12 hour overnight fast, accompanied by baseline ultrasound endothelial assessment or Schirmer’s tear testing when vascular or dry-eye endpoints are targeted. Following initiation, ongoing monitoring is conducted at 1–2 weeks for capillary glucose when paired with antidiabetic therapy, at 4 weeks for acute postprandial glycemic response, tear production, and gastrointestinal tolerability, and at 12 weeks, then every 6 months during continued use to evaluate sustained HbA1c, lipid, and endothelial changes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting Plasma Glucose and 1-Hour Postprandial Glucose Fasting: 70–99 mg/dL (standard reference range); 1-hour post-meal: No established target; reduction from individual baseline is tracked Efficacy marker expected to decrease via SGLT1 inhibition, and safety check that pauses or adjusts use if hypoglycemia (<70 mg/dL) occurs. Fasting blood is drawn after an 8–12 hour overnight fast; 1-hour post-meal glucose is measured after a standardized carbohydrate meal or 75-gram oral glucose tolerance test (Alvarado et al., 2016).
Fasting Serum Insulin and HOMA-IR Fasting insulin: 2–20 µIU/mL (standard reference range); HOMA-IR: No established target; reduction from individual baseline is tracked Efficacy marker expected to decrease as postprandial and fasting insulin demand declines. Homeostatic model assessment for insulin resistance (HOMA-IR, an index estimating insulin resistance from fasting glucose and insulin); blood is drawn after an 8–12 hour overnight fast, and prediabetes trials enroll adults with HOMA-IR >2.5 (NCT07263802).
HbA1c <5.7% (standard reference range) Efficacy marker expected to decrease over 12 weeks in prediabetes, and safety check when combined with antidiabetic drugs. Requires no fasting; retested at 12-week intervals to reflect red blood cell turnover (Alvarado et al., 2016).
Fasting Lipid Panel (LDL-C, HDL-C, Triglycerides) LDL-C: <100 mg/dL (<2.59 mmol/L); HDL-C: ≥40 mg/dL (≥1.03 mmol/L); Triglycerides: <150 mg/dL (<1.70 mmol/L) (standard reference range) Efficacy marker expected to change based on meta-analyses of delphinidin-predominant RCTs. Blood is drawn after a 9–12 hour fast without alcohol for 24 hours and paired with plasma oxLDL where available (Araki et al., 2021; Davinelli et al., 2015).
Brachial FMD and Carotid-Femoral PWV No established target; increase in FMD and reduction in PWV from individual baseline are tracked Efficacy markers expected to change via eNOS activation and reduced arterial stiffness. Morning ultrasound is performed in a fasting, caffeine-free state; acute FMD changes peak 1–2 hours post-dose (Avendano et al., 2026).
Schirmer’s Test and Dry Eye Symptom Scores No established target; increase in Schirmer’s wetting length and reduction in symptom scores from individual baseline are tracked Efficacy markers expected to change when targeting lacrimal tear secretion and ocular dryness. Dry-eye trials enroll adults with baseline Schirmer’s test 5–10 mm/5 min and pair strip wetting with validated dry-eye symptom questionnaires (Kundu et al., 2023; Yamashita et al., 2019).

Qualitative markers to track alongside laboratory testing include:

  • Ocular surface comfort and visual fatigue: Reduced grittiness, burning, and end-of-day screen fatigue during prolonged digital screen work within 2–4 weeks.
  • Post-meal energy stability: Diminished postprandial drowsiness or reactive energy dips 60–120 minutes after carbohydrate-containing meals.
  • Gastrointestinal and hemostatic tolerance: Absence of post-dose nausea, constipation, or unusual skin bruising.

Emerging Research

  • Renal inflammation trial in CKD (NCT07776925): A triple-blind RCT (N = 30, Universidad Mayor, not yet recruiting, completion March 2027) tests 200 mg/day maqui extract for 3 months on C-reactive protein, interleukin-6, uremic toxins, and CKD progression in stage 3–4 CKD; positive results would support renoprotection, whereas null results would refute uremic benefit.
  • Multi-ingredient glycemic trial in prediabetes (NCT07263802): A double-blind RCT (N = 90, Pavia; registered completion date February 2026 has passed, status still listed as not yet recruiting with no results posted) tests 90 days of GlycoDual (maqui, blueberry, cocoa, Gymnema, chromium, zinc) on glycemia; its multi-agent design provides only indirect evidence.
  • Completed vascular reactivity dose-escalation trial (NCT07196059): A crossover study (N = 10 healthy adults, University of Memphis, completed March 2020, no results posted) tested 8-day regimens of 60, 120, and 180 mg/day Delphinol on Vendys II digital thermal endothelial reactivity, perfusion index, and plasma nitrate/nitrite.
  • Completed obesity and inflammaging combination trial (NCT04914312): A double-blind RCT (N = 32 obese adults aged 50–85, Arizona State University, completed August 2023, no results posted) evaluated 56 days of 600 mg/day maqui berry extract plus 2,000 mg eicosapentaenoic acid and 1,000 mg docosahexaenoic acid on inflammatory cytokines.
  • Structure-specific versus null isolated-anthocyanin research: While meta-analyses report superior lipid and vascular effects for delphinidin-predominant extracts (Araki et al., 2021; Avendano et al., 2026), a crossover RCT of 320 mg/day bilberry anthocyanins found null lipid effects (Aboufarrag et al., 2022), underscoring the need for isolated delphinidin trials.

Conclusion

Delphinidins are deep blue-red plant pigments with three oxygen-hydrogen side groups, concentrated in Patagonian maqui berries, bilberries, and blackcurrants. In human studies, oral supplementation with standardized delphinidin-rich extracts shows low-level, indirect evidence for blunting post-meal blood sugar and insulin spikes, improving blood vessel widening and arterial flexibility, decreasing platelet clotting-factor release, and increasing tear fluid production in adults with dry eyes. By contrast, long-term effects on cholesterol profiles and three-month average blood sugar remain conflicted across randomized trials, and cellular aging, brain-protective, and bone-preserving actions are supported only by animal and cell data.

For proactive, longevity-oriented adults, the primary limitation of the evidence base is that every human clinical trial has tested multi-component berry extracts or mixed pigment blends rather than isolated delphinidins. Furthermore, intact delphinidins have very low oral absorption, meaning systemic blood vessel effects likely depend on gut bacterial breakdown into simpler ring-shaped breakdown compounds. Interpretation also requires caution because most positive clinical trials on standardized maqui extracts were funded or co-authored by the ingredient manufacturers and trademark holders, including MNL-Chile, Horphag Research, Anklam Extrakt, and Oryza Oil and Fat Chemical Company, alongside berry industry sponsors such as Agrijohnson and the United States Highbush Blueberry Council, whereas independent trials of berry pigments have reported mixed or null lipid results.

Short-term oral regimens of standardized extracts are well tolerated with zero serious adverse events in human trials, with practical attention centered on pre-meal timing, iron separation, and theoretical interactions with blood-thinning or glucose-lowering medications.

Top - Benefits - Risks - Protocol